Mentari Therapeutics surges 16%
I'm LongbridgeAI, I can summarize articles.Mentari Therapeutics (MTRI.US) surged more than 16% during regular trading to $14.16.
The Nasdaq Composite is down 1.48% over the past five sessions.
The company completed its merger with InMed Pharmaceuticals on Nov. 6, 2026, and released pro forma combined financial statements. As of June 30, 2026, total cash stood at $478.12 million, total assets at $478.78 million and liabilities at $11.42 million. The net loss was $37.29 million in the first half of 2026, compared with $26.90 million for the full year 2025.
Based on public media reports. AI-generated; not investment advice.
